+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Market Spotlight: Cervical Cancer

  • ID: 4421374
  • Report
  • August 2019
  • Region: Global
  • 54 pages
  • Datamonitor Healthcare
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Amgen
  • AstraZeneca
  • Novarti
  • Pinnacle
  • Roche
  • MORE
This Market Spotlight report covers the cervical cancer market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:
  • The author estimates that in 2017, there were 564,900 incident cases of cervical cancer in females worldwide, and expects that number to increase to 618,400 incident cases by 2026.
  • Roche’s Avastin, Mylan’s biosimilar bevacizumab, Amgen’s Mvasi, and Pfizer's Zirabev, which target vascular endothelial growth factor; Novartis’s Hycamtin, a topoisomerase I inhibitor; Pinnacle’s Photofrin, a photodynamic therapy; and Merck’s Keytruda, an anti-PD-1 antibody, are the marketed drugs available for cervical cancer. The majority of the marketed drugs are administered via the intravenous route.
  • The majority of the industry-sponsored drugs in active clinical development for cervical cancer are in Phase II. Therapies in development for cervical cancer focus on a wide variety of targets. The majority of the pipeline drugs are administered via the intravenous route, with the remainder being oral, subcutaneous, intramuscular, and intranasal formulations.
  • The release of topline Phase III trial results for Libtayo is the only high-impact upcoming event in the cervical cancer space. The overall likelihood of approval of a Phase I solid tumors asset is 5.8%, and the average probability a drug advances from Phase III is 40.3%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
  • There have been 11 licensing and asset acquisition deals involving cervical cancer drugs during 2014–19. The $727.5m license agreement signed in 2015 between Inovio and MedImmune for the exclusive rights to develop and market Inovio's INO-3112 was the largest deal.
  • The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for cervical cancer have been in the early and mid-phases of development, with 94% of trials in Phase I–II, and only 6% in Phase III–IV.
  • The US has a substantial lead in the number of cervical cancer clinical trials globally. The UK leads the major EU markets, while South Korea has the top spot in Asia.
  • AstraZeneca has the highest number of ongoing clinical trials for cervical cancer, with 13 trials.
  • AstraZeneca and Roche lead industry sponsors with the highest number of clinical trials for cervical cancer.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Amgen
  • AstraZeneca
  • Novarti
  • Pinnacle
  • Roche
  • MORE
OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT
  • Surgery
  • Radiotherapy
  • Chemotherapy
  • Targeted therapy
  • Immunotherapy
EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION
  • LN-145 for Cervical Cancer (July 2, 2019)
  • Axalimogene Filolisbac for Cervical Cancer (June 27, 2019)
  • Mvasi for Cervical Cancer (June 25, 2019)
  • LN-145 for Cervical Cancer (May 31, 2019)
  • Axalimogene Filolisbac for Cervical Cancer (May 15, 2019)
  • LN-145 for Cervical Cancer (May 15, 2019)
  • Sacituzumab Govitecan for Cervical Cancer (April 29, 2019)
  • Nerlynx for Cervical Cancer (April 01, 2019)
  • Nerlynx for Cervical Cancer (March 18, 2019)
  • Axalimogene Filolisbac for Cervical Cancer (January 23, 2019)
  • Nerlynx for Cervical Cancer (January 11, 2019)
  • Axalimogene Filolisbac for Cervical Cancer (July 13, 2018)
  • Multiple Drugs for Cervical Cancer (March 9, 2018)
KEY UPCOMING EVENTS

KEY REGULATORY EVENTS
  • Pfizer Could Launch US Bevacizumab This Year Despite Patent Thicket
  • Iovance Snags BTD For Cervical Cancer With Small Efficacy Sample Size
PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS
  • US Merck Links With Tessa On Keytruda Combo For Cervical Cancer
  • Advaxis Stumbles Further As Amgen Exits Early-Stage Cancer Immunotherapy Pact
PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase
BIBLIOGRAPHY
  • Prescription information
APPENDIX

LIST OF FIGURES
Figure 1: Trends in incident cases of cervical cancer, 2017–26
Figure 2: Overview of pipeline drugs for cervical cancer in the US
Figure 3: Pipeline drugs for cervical cancer, by company
Figure 4: Pipeline drugs for cervical cancer, by drug type
Figure 5: Pipeline drugs for cervical cancer, by classification
Figure 6: LN-145 for Cervical Cancer (May 31, 2019): Phase II - innovaTIL-04 (C-145-04)
Figure 7: LN-145 for Cervical Cancer (May 15, 2019): Phase II - innovaTIL-04 (C-145-04)
Figure 8: Nerlynx for Cervical Cancer (March 18, 2019): Phase II - SUMMIT - w/Fulvestrant (HER2-low/HER2mut)
Figure 9: Key upcoming events in cervical cancer
Figure 10: Probability of success in the cervical cancer pipeline
Figure 11: Licensing and asset acquisition deals in cervical cancer, 2014–19
Figure 12: Parent patents in cervical cancer
Figure 13: Clinical trials in cervical cancer
Figure 14: Top 10 drugs for clinical trials in cervical cancer
Figure 15: Top 10 companies for clinical trials in cervical cancer
Figure 16: Trial locations in cervical cancer
Figure 17: Cervical cancer trials status
Figure 18: Cervical cancer trials sponsors, by phase

LIST OF TABLES
Table 1: Incident cases of cervical cancer, 2017–26
Table 2: Marketed drugs for cervical cancer
Table 3: Pipeline drugs for cervical cancer in the US
Table 4: LN-145 for Cervical Cancer (July 2, 2019)
Table 5: Axalimogene Filolisbac for Cervical Cancer (June 27, 2019)
Table 6: Mvasi for Cervical Cancer (June 25, 2019)
Table 7: LN-145 for Cervical Cancer (May 31, 2019)
Table 8: Axalimogene Filolisbac for Cervical Cancer (May 15, 2019)
Table 9: LN-145 for Cervical Cancer (May 15, 2019)
Table 10: Sacituzumab Govitecan for Cervical Cancer (April 29, 2019)
Table 11: Nerlynx for Cervical Cancer (April 01, 2019)
Table 12: Nerlynx for Cervical Cancer (March 18, 2019)
Table 13: Axalimogene Filolisbac for Cervical Cancer (January 23, 2019)
Table 14: Nerlynx for Cervical Cancer (January 11, 2019)
Table 15: Axalimogene Filolisbac for Cervical Cancer (July 13, 2018)
Table 16: Multiple Drugs for Cervical Cancer (March 9, 2018)
Table 17: Historical global sales, by drug ($m), 2014–18
Table 18: Forecasted global sales, by drug ($m), 2019–23
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Novarti
  • Roche
  • Amgen
  • AstraZeneca
  • Pinnacle
Note: Product cover images may vary from those shown
Adroll
adroll